PDCD4 and CDX-2 as immunohistochemical markers of gastric mucosa atrophy in chronic gastritis-Reference-Cited by-同舟云学术

PDCD4 and CDX-2 as immunohistochemical markers of gastric mucosa atrophy in chronic gastritis

Published:2023-04-29 Issue:2 Volume:22 Page:40-48
ISSN:2071-5943
Container-title:Ural Medical Journal
language:
Short-container-title:jour

Author:

Rubtsov V. A.¹^ORCID,Shimanskaya A. G.¹^ORCID,Parygina М. N.¹^ORCID,Mozgovoi S. I.¹^ORCID,Pomorgailo E. G.¹^ORCID,Kononov A. V.¹^ORCID

Affiliation:

1. Omsk State Medical University

Abstract

Introduction Diagnosis of the gastric mucosa atrophy represents an important problem, the solution of which depends on the possibility of secondary prevention of gastric cancer. A possible way of solution is the use of immunohistochemical markers - proteins associated with cellular remodeling of gastric mucosa, PDCD4 and CDX2.The aim of the work is to evaluate the possibility of using immunohistochemical markers PDCD4 and CDX-2 to diagnose atrophy of the gastric mucosa in chronic gastritis and increase the informative value of biopsy examination.Materials and method The object of the study was 155 cases of biopsy examination of the gastric mucosa of patients with chronic gastritis (5 fragments per case − 775 biopsy specimens). A comparative semi-quantitative assessment of immunohistochemical expression of CDX2, PDCD4 at different stages of chronic gastritis was performed. Spearman correlation coefficient was used to assess correlation relationship.Results There were no statistically significant differences in the level of PDCD4 in studied samples depending on the stage of chronic gastritis, p=0.06. Statistically significant increase of CDX2sum index in progressing stage of chronic atrophic gastritis (p=0.005), demonstrated a pronounced positive correlation r=0.70 (p<0.01).Discussion According to the results obtained, it is shown that the decline in PDCD4 protein does not occur with the progression of atrophy severity. Complementary use of immunohistochemical marker CDX2 is able to give an idea of the presence and severity of both metaplastic and absolute atrophic changes in the gastric mucosa.Conclusion Equally high level of PDCD4 protein index in the gastric mucosa at different stages of chronic gastritis excludes the possibility of its use as an immunohistochemical marker of atrophy. Semi-quantitative immunohistochemical index of CDX2 protein can be used as an additional marker in decision support system for assessment of atrophic changes in gastric mucosa.

Publisher

Ural State Medical University

Subject

General Medicine

Reference30 articles.

1. Correa P. Chronic gastritis: a clinico-pathological classification. Am J Gastroenterol 1988;83(5):504−509.

2. Rugge M, Genta RM, Graham DY et al. Chronicles of a cancer foretold: 35 years of gastric cancer risk assessment. Gut 2016;65(5):721−725. https://doi.org/10.1136/gutjnl-2015-310846.

3. Lash JG, Genta RM. Adherence to the sydney system guidelines increases the detection of helicobacter gastritis and intestinal metaplasia in 400738 sets of gastric biopsies. Aliment Pharmacol Ther 2013;38(4):424−431. https://doi.org/10.1111/apt.12383.

4. Kononov AV, Mozgovoy SI, Pomorgailo EG et al. Molecular and cellular basis in prediction of gastric cancer: a multidisciplinary research experience. Ural medical journal 2017;148(4):9−18. (In Russ.).

5. Chen HY, Hu Y, Lu NH et al. Caudal type homeoboxes as a driving force in Helicobacter pylori infection-induced gastric intestinal metaplasia. Gut Microbes 2020;12(1):1−12. https://doi.org/10.1080/19490976.2020.1809331.